No.	Recommendations/Statements	GRADE	Sources
19.1.	HPV-based screening performed every 3 years has a relatively favorable cost-effectiveness ratio. Compared to annual cytology-based screening, HPV-based screening has a similar expected benefit and a lower expected harm (e.g. surgical interventions, colposcopies, psychological stress caused by abnormal findings and follow-up examinations).	⊕⊖⊖⊖	[cf. Guideline Report and Evidence Report]
19.2.	In Germany, HPV-based screening carried out at intervals of every 3 – 5 years is considered to be cost-effective. HPV-based screening carried out at intervals of every 2 years has a less favorable cost-effectiveness ratio. Annual screening significantly increases costs without generating a significant additional benefit.	⊕⊖⊖⊖	158